PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies"
Version 1
: Received: 21 June 2023 / Approved: 23 June 2023 / Online: 23 June 2023 (09:44:00 CEST)
How to cite:
verma, H.; Panda, P.; LVKS, B. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies". Preprints2023, 2023061650. https://doi.org/10.20944/preprints202306.1650.v1
verma, H.; Panda, P.; LVKS, B. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies". Preprints 2023, 2023061650. https://doi.org/10.20944/preprints202306.1650.v1
verma, H.; Panda, P.; LVKS, B. Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies". Preprints2023, 2023061650. https://doi.org/10.20944/preprints202306.1650.v1
APA Style
verma, H., Panda, P., & LVKS, B. (2023). Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies". Preprints. https://doi.org/10.20944/preprints202306.1650.v1
Chicago/Turabian Style
verma, H., Poojarani Panda and Bhaskar LVKS. 2023 "Precision Medicine Revolutionizing Esophageal Cancer Treatment: Surmounting Hurdles and Enhancing Therapeutic Efficacy through Targeted Drug Therapies"" Preprints. https://doi.org/10.20944/preprints202306.1650.v1
Abstract
Esophageal cancer is a formidable challenge in the realm of cancer treatment. Conventional methods such as surgery, chemotherapy, and immunotherapy have demonstrated limited success rates in managing this disease. In response, targeted drug therapies have emerged as a promising strategy to improve outcomes for patients. These therapies aim to disrupt specific pathways involved in the growth and development of esophageal cancer cells. This review explores various drugs used to target specific pathways, including cetuximab and monoclonal antibodies (gefitinib) that target the epidermal growth factor receptor (EGFR), trastuzumab that targets human epidermal growth factor receptor 2 (HER-2), drugs targeting the vascular endothelial growth factor receptor (VEGFR), mTOR inhibitors, and cMET inhibitors. Additionally, the article discusses the impact of drug resistance on the effectiveness of these therapies, highlighting factors such as cancer stem cells, cancer-associated fibroblasts, immune-inflammatory cells, cytokines, hypoxia, and growth factors. While drug targeting approaches do not provide a complete cure for esophageal cancer due to drug resistance and associated side effects, they offer potential for improving patient survival rates.
Keywords
Esophageal cancer; Targeted drug therapies; Pathway targeting; Drug resistance; Patient survival rates
Subject
Biology and Life Sciences, Other
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
